A detailed history of Royal Bank Of Canada transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 51,582 shares of RNA stock, worth $1.79 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
51,582
Previous 10,109 410.26%
Holding current value
$1.79 Million
Previous $412,000 475.0%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$37.21 - $48.14 $1.54 Million - $2 Million
41,473 Added 410.26%
51,582 $2.37 Million
Q2 2024

Aug 14, 2024

BUY
$22.73 - $40.85 $158,428 - $284,724
6,970 Added 222.05%
10,109 $412,000
Q1 2024

Nov 05, 2024

SELL
$9.16 - $25.52 $63,845 - $177,874
-6,970 Reduced 68.95%
3,139 $80,000
Q1 2024

May 15, 2024

SELL
$9.16 - $25.52 $190,573 - $530,943
-20,805 Reduced 86.89%
3,139 $80,000
Q4 2023

Feb 14, 2024

BUY
$4.87 - $9.37 $57,738 - $111,090
11,856 Added 98.08%
23,944 $216,000
Q3 2023

Nov 14, 2023

BUY
$6.3 - $11.35 $27,808 - $50,098
4,414 Added 57.52%
12,088 $77,000
Q2 2023

Aug 14, 2023

BUY
$10.62 - $17.34 $34,833 - $56,875
3,280 Added 74.65%
7,674 $85,000
Q1 2023

May 15, 2023

SELL
$15.35 - $25.65 $44,376 - $74,154
-2,891 Reduced 39.68%
4,394 $67,000
Q4 2022

Feb 14, 2023

BUY
$10.06 - $22.66 $60,792 - $136,934
6,043 Added 486.55%
7,285 $161,000
Q3 2022

Nov 14, 2022

BUY
$15.46 - $23.43 $13,419 - $20,337
868 Added 232.09%
1,242 $20,000
Q2 2022

Aug 15, 2022

SELL
$11.18 - $20.5 $27,256 - $49,979
-2,438 Reduced 86.7%
374 $5,000
Q1 2022

May 16, 2022

SELL
$14.2 - $23.78 $72,604 - $121,587
-5,113 Reduced 64.52%
2,812 $52,000
Q4 2021

Feb 14, 2022

BUY
$20.4 - $28.66 $2,754 - $3,869
135 Added 1.73%
7,925 $189,000
Q3 2021

Nov 15, 2021

BUY
$18.16 - $25.21 $17,143 - $23,798
944 Added 13.79%
7,790 $192,000
Q2 2021

Aug 16, 2021

BUY
$19.62 - $29.26 $134,318 - $200,313
6,846 New
6,846 $169,000

Others Institutions Holding RNA

About Avidity Biosciences, Inc.


  • Ticker RNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,127,000
  • Market Cap $1.81B
  • Description
  • Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...
More about RNA
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.